Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Synonyms
Deferasiroxum
Deferasirox
Brand Names
Deferasirox (type J)
PMS-deferasirox (type J)
Taro-deferasirox (type J)
Deferasirox Oral Granules
Jadenu
Sandoz Deferasirox (type J)
Sandoz Deferasirox
Jamp Deferasirox (type J)
Exjade
Deferasirox oral
PMS-deferasirox
Taro-deferasirox
Deferasorox
Deferasirox
Auro-deferasirox (type J)
Teva-deferasirox (type J)
Deferasirox Mylan
Teva-deferasirox
Apo-deferasirox
Apo-deferasirox (type J)
Deferasirox Accord
Indication
For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Categories
Acids, Carbocyclic
Benzene Derivatives
Benzoates
Chelating Agents
Compounds used in a research, industrial, or household setting
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682